Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

Abstract

This pooled analysis shows that linagliptin is well tolerated, with a low risk of hypoglycaemia.

Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

“…Reassuring hepatic safety data have also been reported with linagliptin as shown in a meta-analysis of 8 placebo-controlled trials (Table 2) [48] . In the only study where a DPP-4 inhibitor (5 mg linagliptin) was administered once daily for 7 days in patients with mild and moderate HI, the DPP-4 inhibitor was well tolerated [47] .…”

“…However, it is always difficult to confirm a causal relationship in such observational reports because of the presence of many confounding factors [37] . Pooled analyses of large clinical trials with sitagliptin [34] , vildagliptin [40] and linagliptin [48] (Table 2) as well as data from the two recently published major cardiovascular outcome studies reporting liver safety data with saxagliptin [45] and alogliptin [53] (Table 3) are reassuring. On the contrary, some preliminary data suggested that inhibition of DPP-4 might be beneficial in CLD [74,75] .…”

“…Thus, caution is recommended, especially in patients with advanced cirrhosis for whom the problem of controlling effectively and safely blood glucose becomes more crucial and most often requires insulin therapy. or (% CV)* Sitagliptin 100 mg [26] 157 (73) 170 (37) 150 (55) 103 (67) Saxagliptin 10 mg [42,43] [34] , vildagliptin [40] and linagliptin [48] .…”

Efficacy and safety of Jentadueto® (linagliptin plus metformin)

“…The safety profile of linagliptin has been analyzed in detail in previous dedicated reviews 24,69,70 and is generally good and quite similar to that previously reported with other DPP-4 inhibitors (i.e. almost comparable to that of placebo) 8,73,74 .…”

“…The safety profiles of each separate glucose-lowering agent, the biguanide compound metformin 4,49,50 or the DPP-4 inhibitor linagliptin 24,69,70 , are well documented. The most commonly reported adverse effects associated with metformin therapy are gastrointestinal, and include abdominal pain, diarrhea, nausea, and anorexia.…”